TTD | Drug: D09POQ

Drug General Information
Drug ID	D09POQ
Former ID	DIB004377
Drug Name	OM-174
Indication	Cancer [ICD9: 140-229; ICD10:C00-C96]		Phase 1	[524222]
Company	OM Pharma
Formula	C53H102N2O20P2
CAS Number	CAS 171092-39-0
PubChem Compound ID	56841121
Target and Pathway
Target(s)	Toll-like receptor 4	Target Info	Modulator	[532290]
Target(s)	Toll-like receptor 2	Target Info	Modulator	[532290]
KEGG Pathway	NF-kappa B signaling pathway
	HIF-1 signaling pathway
	Phagosome
	PI3K-Akt signaling pathway
	Toll-like receptor signaling pathway
	Pathogenic Escherichia coli infection
	Salmonella infection
	Pertussis
	Legionellosis
	Leishmaniasis
	Chagas disease (American trypanosomiasis)
	Malaria
	Toxoplasmosis
	Amoebiasis
	Tuberculosis
	Hepatitis B
	Measles
	Influenza A
	Proteoglycans in cancer
	Inflammatory bowel disease (IBD)
	Rheumatoid arthritishsa04145:Phagosome
	Herpes simplex infection
	Rheumatoid arthritis
NetPath Pathway	IL5 Signaling Pathway
	IL2 Signaling Pathway
	IL4 Signaling PathwayNetPath_16:IL4 Signaling Pathway
	TCR Signaling Pathway
PANTHER Pathway	Toll receptor signaling pathwayP00054:Toll receptor signaling pathway
Pathway Interaction Database	Endogenous TLR signalingtoll_endogenous_pathway:Endogenous TLR signaling
Reactome	Ligand-dependent caspase activation
	Toll Like Receptor 4 (TLR4) Cascade
	MyD88:Mal cascade initiated on plasma membrane
	MyD88-independent TLR3/TLR4 cascade
	TRIF-mediated programmed cell death
	MyD88 deficiency (TLR2/4)
	IRAK4 deficiency (TLR2/4)
	Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon
	IKK complex recruitment mediated by RIP1
	TRAF6 mediated induction of TAK1 complexR-HSA-1461957:Beta defensins
	Toll Like Receptor TLR6:TLR2 Cascade
WikiPathways	Toll-like receptor signaling pathway
	Toll-Like Receptors Cascades
	MyD88:Mal cascade initiated on plasma membrane
	MyD88-independent cascade
	Primary Focal Segmental Glomerulosclerosis FSGS
	Spinal Cord Injury
	Corticotropin-releasing hormone
	Pathogenic Escherichia coli infection
	Regulation of toll-like receptor signaling pathwayWP75:Toll-like receptor signaling pathway
	IL1 and megakaryotyces in obesity
	Human Complement System
	Defensins
	Regulation of toll-like receptor signaling pathway
References
Ref 524222	ClinicalTrials.gov (NCT01800812) Effects of OM-174 in Adult Patients With Solid Tumors. U.S. National Institutes of Health.
Ref 532290	Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors. BMC Cancer. 2013 Apr 2;13:172.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.

Drug Information